¼¼°è °¨¿° °ü¸® ½ÃÀå ±Ô¸ð´Â 2024³â 281¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. IMARC GroupÀº ÇâÈÄ 2033³â¿¡´Â 497¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 6.22%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ÀÌÀ¯´Â źźÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í »ì±Õ-¼Òµ¶ ±â¼úÀÇ º¸±Þ¿¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áø´Ü ¹× °¨¿° °ü¸® ±â±âÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü, ¼öÀÇ»ç ¹× µ¿¹° ÀÇ·á ÇöÀå ¼ö¿ä Áõ°¡, °¨¿° ¿¹¹æ¿¡ ´ëÇÑ ¿¬±¸°³¹ß Áõ°¡, ÀÇ·á °ü·Ã °¨¿°(HAI) ¿¹¹æ¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
ÀÏ¹Ý ½Ã¹Î°ú ÀÇ·á±â°üÀÇ À§»ý°ú ¾ÈÀü¿¡ ´ëÇÑ ÀνÄÀÌ »ó´çÈ÷ ³ô¾ÆÁ³½À´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â 2Â÷ ¿À¿°À» ÇÇÇϱâ À§ÇØ ¸ê±Õ°ú À§»ýÀ» Áß¿äÇÏ°Ô »ý°¢ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀº ȯÀڵ鿡°Ôµµ È®»êµÇ¾î ÀÇ·á±â°üÀÌ °¨¿° °ü¸®¿¡ ´õ ¸¹Àº ÀÚ¿øÀ» ÇÒ´çÇϵµ·Ï µ¿±â¸¦ ºÎ¿©Çϰí ÀÖ½À´Ï´Ù. º¸´Ù ¾ÈÀüÇÑ È¯°æÀ» Ãß±¸ÇÏ´Â ¿òÁ÷ÀÓÀº ¾÷°è¿¡¼ Á¦Ç° ¹× ÇÁ·ÎÅäÄÝÀ» °ÈÇØ¾ß ÇÒ Çʿ伺À» Áö¼ÓÀûÀ¸·Î Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Òµ¶ Åø¿Í ¼Ò¸ðǰÀÇ ¹ßÀüÀº ±× È¿°ú¿Í »ç¿ë ÆíÀǼºÀ» ¸ðµÎ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÚµ¿ÈµÈ ¸ê±Õ ½Ã½ºÅÛ, °ÈµÈ ¾à¹° ó¹æ, ½Ç½Ã°£ ¸ð´ÏÅ͸µ ÅøÀº ÀÌÁ¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº °á°ú¸¦ °³¼±ÇÏ´Â µ¿½Ã¿¡ ³ëµ¿·Â°ú Àå±âÀûÀÎ ºñ¿ëÀ» Àý°¨ÇÏ¿© Çö´ëÀÇ ÇコÄÉ¾î ºñÁî´Ï½º¿¡ ¸Å·ÂÀûÀÎ ÅõÀÚó°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î ´ë±â ¼ö¼ú ¹× ÀÀ±Þ ¼ö¼ú Áõ°¡·Î ¹«±Õ ȯ°æÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ö¼ú½Ç¿¡¼´Â ´Ù¾çÇÑ ºñǰ ¹× ±â±¸¸¦ »ç¿ëÇÏ¿© ¾ö°ÝÇÑ Á¶Ä¡°¡ ÇÊ¿äÇÕ´Ï´Ù. ¼ö¼ú °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±ÕÀÏÇÑ °¨¿° °ü¸®ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁ® ÀÇ·á ±â°ü¿¡ ÀÖÀ¸¸ç, Áß¿äÇÑ ºÐ¾ß°¡ µÇ¾ú½À´Ï´Ù.
³ëÀÎ Àα¸ Áõ°¡
°¨¿° °ü¸® ½ÃÀå Çü¼º¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼¼°è ³ëÀÎ Àα¸ Áõ°¡°¡ ´«¿¡ ¶ç°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ¿¹Ãø¿¡ µû¸£¸é 2030³â¿¡´Â Àü ¼¼°è Àα¸ 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÌ µÉ °ÍÀ̸ç, Àü ¼¼°è ³ëÀÎ Àα¸´Â 2020³â 10¾ï ¸í¿¡¼ 2030³â¿¡´Â ¾à 14¾ï ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2050³â¿¡´Â ÀÌ ¼öÄ¡°¡ ¾à 21¾ï ¸íÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ³ëÀÎÀº ÀϹÝÀûÀ¸·Î ¸é¿ª·ÂÀÌ ¾àÇÏ°í °¨¿°¿¡ Ãë¾àÇϹǷΠÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû º¯È´Â ÀÇ·á ½Ã½ºÅÛ¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ¿¡ µû¶ó º´¿ø, ³ëÀοä¾ç½Ã¼³, Àå±â¿ä¾ç½Ã¼³ÀÇ ¾ö°ÝÇÑ °¨¿°°ü¸® ´ëÃ¥ÀÇ Çʿ伺ÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ À§»ý ±âÁØÀ» ÁؼöÇϰí ÃÖ÷´Ü ¸ê±Õ ¹æ¹ýÀ» µµÀÔÇÏ´Â °ÍÀº ÀÌ ¿¬·É´ë¸¦ °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº °¨¿° °ü¸® ½ÃÀå ¿¹Ãø¿¡ ´õ¿í ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
ÀÇ·á °ü·Ã °¨¿°(HAI) À¯º´·ü »ó½Â
´Ù¾çÇÑ Áö¿ªÀÇ º´¿ø ¹× ÀÓ»ó ȯ°æ¿¡¼ ÀÇ·á °ü·Ã °¨¿°(HAI)ÀÇ ºóµµ°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀÎ °¨¿° °ü¸® Àü·«ÀÇ Çʿ伺ÀÌ Å©°Ô ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú ºÎÀ§ °¨¿°, Ä«Å×ÅÍ °ü·Ã °¨¿°, ÀΰøÈ£Èí±â °ü·Ã Æó·Å µî ºó¹øÇÏ°Ô ¹ß»ýÇÏ´Â HAI´Â ȯÀÚ¿¡°Ô ½É°¢ÇÑ °Ç°»óÀÇ À§ÇèÀ» ÃÊ·¡Çϰí, ÀÔ¿ø ±â°£ ¿¬Àå, ÀÇ·áºñ Áõ°¡, ÀÌȯÀ² »ó½ÂÀ¸·Î À̾îÁý´Ï´Ù. À¯·´Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(European Centre for Disease Prevention and Control)ÀÇ ¹ßÇ¥¿¡ µû¸£¸é EU/EEA¿¡¼´Â ¸Å³â 430¸¸ ¸í¿¡ °¡±î¿î º´¿ø ȯÀÚ°¡ Àû¾îµµ ÇÑ ¹ø ÀÌ»ó HAI¿¡ °¨¿°µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿ì·Á½º·¯¿î Åë°è´Â °¨¿° ¿¹¹æ ´ëÃ¥ÀÇ °³¼±°ú ÃÖ÷´Ü ¼Òµ¶ ¹× ¸ê±Õ ±â¼ú µµÀÔÀÇ Çʿ伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇÏ°í ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇϱâ À§ÇØ °¨¿° °ü¸® Á¦Ç°¿¡ ÀÚ¿øÀ» Á¡Â÷ÀûÀ¸·Î ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. °¨¿°·ü °¨¼Ò¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ °¨¿° °ü¸® »ê¾÷ÀÇ ¼ºÀåÀÌ °ÈµÇ°í ÀÖ½À´Ï´Ù.
¿Ü·¡ ¼ºñ½º »ê¾÷ È®´ë
¿Ü·¡È¯ÀÚ¸¦ À§ÇÑ ¼ºñ½º·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖ´Â °ÍÀÌ °¨¿°°ü¸® Á¦Ç° ¹× ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿Ü·¡ ȯÀÚ ÄÉ¾î ¼¾ÅÍ´Â ÇÏ·í¹ã ÀÔ¿øÇÏÁö ¾Ê°íµµ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϸç, ±× Æí¸®¼º, Àú·ÅÇÑ °¡°Ý, Á¢±Ù¼º ¶§¹®¿¡ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. IMARC GroupÀÇ º¸°í¼¿¡ µû¸£¸é ¼¼°è ¿Ü·¡È¯ÀÚ ¼ºñ½º ½ÃÀåÀº 2023³â 3Á¶ 8,000¾ï ´Þ·¯ÀÇ Æò°¡¾×À» ´Þ¼ºÇϰí 2024-2032³â 5.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2032³â±îÁö 6Á¶ 3,000¾ï ´Þ·¯·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ È®´ë¿¡ µû¶ó ¿Ü·¡¿¡¼ Ä¡·á¸¦ ¹Þ´Â ȯÀÚ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¾ö°ÝÇÑ °¨¿° °ü¸® ´ëÃ¥ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ȯÀÚ ±³Ã¼°¡ Àæ°í, Ä¡·á ÁֱⰡ ºü¸£¸ç, 2Â÷ ¿À¿°À» ÇÇÇØ¾ß ÇϹǷΠÀÌ·¯ÇÑ ½Ã¼³¿¡¼´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ¸ê±Õ, Ç¥¸é ¼Òµ¶, °³ÀÎ º¸È£ Á¶Ä¡°¡ ¿ä±¸µË´Ï´Ù. ¿Ü·¡ ȯÀÚÀÇ ¾ÈÀü°ú ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼ °¨¿° °ü¸® ½ÃÀåÀÇ ¸ÅÃâÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
±â¼ú ¹ßÀü°ú Á¦Ç° Çõ½Å
¼Òµ¶ ¹× ¸ê±Õ ±â¼úÀÇ ¹ßÀüÀº °¨¿° °ü¸® ½ÃÀåÀ» º¯È½Ã۰í ÀÖÀ¸¸ç, Á¤È®¼º, È¿À²¼º, º¯ÈÇÏ´Â ÀÓ»óÀû ¿ä±¸¿¡ ´ëÇÑ ÀûÇÕ¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. Àç·á, ÀÚµ¿È ½Ã½ºÅÛ, ÈÇй°Áú, ¸ð´ÏÅ͸µ Ç÷§ÆûÀÇ ¹ßÀüÀ¸·Î °¨¿° °ü¸®ÀÇ ½Å·Ú¼º°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±× ´ëÇ¥ÀûÀÎ ¿¹°¡ ¿¿¡ ¹Î°¨ÇÑ ¼ö¼ú±â±¸¸¦ À§ÇØ Æ¯º°È÷ ¼³°èµÈ Àú¿Â VH2O2 »ì±Õ±âÀÎ GetingeÀÇ Poladus 150ÀÇ 2024³â Ãâ½ÃÀÔ´Ï´Ù. ÀÌ Á¦Ç°Àº ÀÇ·á °ü·Ã °¨¿°À» ÃÖ¼ÒÈÇÏ¸é¼ ¹«±Õ °ø±Þ ÀåÄ¡ÀÇ °øÁ¤À» ÃÖÀûÈÇÏ´Â µ¿½Ã¿¡ ÀÇ·á °ü·Ã °¨¿°À» ÃÖ¼ÒÈÇϵµ·Ï ¼³°èµÈ ÃÖ÷´Ü ±³Â÷ ¿À¿° ¹æÁö ±â¼úÀ» Ư¡À¸·Î ÇÕ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¶ÇÇÑ µðÁöÅÐ Ç÷§Æû°ú ¿¬°áÇÏ¿© º´¿ø³» Àçó¸®ÀÇ ÃßÀû¼º°ú ÀÛ¾÷ È¿À²À» Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ ÀÇ·áÁøÀº ¸ê±Õ ÀýÂ÷¸¦ ±ÕÀÏÈÇÏ°í ½Ç¼ö¸¦ ÁÙÀÌ¸é¼ ¸ê±Õ ÀýÂ÷¸¦ ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÚµ¿È, ÃßÀû °¡´ÉÇÑ ½Ã½ºÅÛ, Á÷°üÀûÀÎ ÀÎÅÍÆäÀ̽º¿¡ ÁßÁ¡À» µÎ¾î ³ëµ¿ Áý¾àÀûÀÎ ÀÛ¾÷À» ÃÖ¼ÒÈÇÏ°í ±ÔÁ¦ Áؼö¸¦ °ÈÇÕ´Ï´Ù. ÀÇ·á Á¾»çÀÚµé »çÀÌ¿¡¼ ÀÌ·¯ÇÑ ±â¼úÀÇ ºñ¿ë ¹× ¾ÈÀü»óÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó µµÀÔÀÌ °¡¼Óȵǰí ÀÖ½À´Ï´Ù.
°øÁߺ¸°Ç Ä·ÆäÀΰú Á¤ºÎÀÇ ±¸»ó
Á¤ºÎ ÁÖµµÀÇ °øÁߺ¸°Ç Ä·ÆäÀΰú Á¤Ã¥ ±¸»óÀº °¨¿° °ü¸® ´ëÃ¥À» °ÈÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ±¸»óÀº À§»ý¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í, Ç×±ÕÁ¦ÀÇ Ã¥ÀÓ°¨ ÀÖ´Â »ç¿ëÀ» Àå·ÁÇϸç, ÀÓ»ó ¹× Áö¿ª ȯ°æ¿¡¼ÀÇ º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ Á¦½ÃÇÕ´Ï´Ù. Á¤ºÎ ±â°üÀº °ø°ø º´¿øÀÇ °¨¿° °ü¸® ½Ã½ºÅÛ °È, Áؼö¿¡ ´ëÇÑ Àμ¾Æ¼ºê Á¦°ø, °¨¿° ÆÐÅÏÀ» ÃßÀûÇÏ´Â °¨½Ã ³ë·Â¿¡ ÀÚÁÖ ÀÚ¿øÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. º¸°ÇÀÇ·á ±¹°¡ Àü·«Àº °¨¿° ¿¹¹æÀ» Áß¿äÇÑ ¸ñÇ¥·Î »ï°í, ÀÇ·á±â°üÀÌ º¸´Ù ±¤¹üÀ§ÇÑ º¸°ÇÀÇ·á ¸ñÇ¥¿¡ ºÎÇÕÇÒ ¼ö ÀÖµµ·Ï ¹è·ÁÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Àü¹®°¡¿Í ÀϹÝÀÎ ¸ðµÎ¸¦ ´ë»óÀ¸·Î ÇÑ ±³À°Àû È«º¸´Â °¨¿° À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ´Â Çൿ ¼öÁ¤À» °ÈÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä·ÆäÀÎÀº ¶ÇÇÑ ¼Òµ¶Á¦, »ì±ÕÁ¦, º¸È£ Àåºñ µî Ç¥ÁØÈµÈ ǰ¸ñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ƯÈ÷ Àǽİú ÀÎÇÁ¶ó°¡ ¾ÆÁ÷ °³¹ßÁßÀÎ °³¹ßµµ»ó±¹¿¡¼ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇÏ´Â µ¿½Ã¿¡ °ø°øÀÇ ¾ÈÀüÀ» °ÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
»ê¾÷°è Çù·Â
ÀÇ·á±â±â Á¦Á¶¾÷ü¿Í ÇコÄɾî ÀÌÇØ°ü°èÀÚ¿ÍÀÇ Çù¾÷Àº °¨¿°°ü¸® ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çù·ÂÀº ƯÈ÷ °¨¿° ¿¹¹æ°ú °°Àº ÇコÄɾîÀÇ Áß¿äÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§ÇÑ Ã·´Ü ±â¼ú¿¡ ´ëÇÑ ÀνÄ, ±³À°, Ȱ¿ëÀ» ÃËÁøÇÕ´Ï´Ù. ÃÖ±Ù Àεµ¿¡¼ °³ÃÖµÈ CRITICARE 2025¿¡¼ ¹ÚƼ°¡µå¿Í BD°¡ °øµ¿À¸·Î ÀÇ·á °ü·Ã °¨¿°(HAI)°ú Ç×±ÕÁ¦ ³»¼º(AMR), ƯÈ÷ ÁßȯÀÚ½Ç È¯°æ¿¡¼ ÀÇ·á °ü·Ã °¨¿°(HAI) ¹× Ç×±ÕÁ¦ ³»¼º(AMR)¿¡ ´ëÇÑ ´ëÀÀÀÇ Á߿伺À» °Á¶ÇÑ ¹Ù ÀÖ½À´Ï´Ù. À̹ø Çà»ç¸¦ ÅëÇØ ¹ÚƼ°¡µå ÄÚÆÃ Ä«Å×ÅͰ¡ Ä«Å×ÅÍ °ü·Ã ¿ä·Î°¨¿°(CAUTI)À» ÁÙÀ̰í Ã¥ÀÓ°¨ ÀÖ´Â Ç×»ýÁ¦ »ç¿ëÀ» ÃËÁøÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¹ÚƼ°¡µå ÄÚÆÃ Ä«Å×ÅÍÀÇ ÀÌÁ¡ÀÌ °Á¶µÇ¾ú½À´Ï´Ù. BD´Â ¶ÇÇÑ Àεµ ½ÃÀå¿¡¼ ÀÌ·¯ÇÑ ÃÖ÷´Ü ÀåÄ¡ÀÇ Ãâ½Ã°¡ ÀÓ¹ÚÇßÀ½À» ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ ±¸»óÀº ¼ö¿ä°¡ ¸¹Àº Áö¿ª¿¡ ÷´Ü ±â¼úÀ» µµÀÔÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ¼¼°è °¨¿° °ü¸® ¸ñÇ¥ ´Þ¼º, ȯÀÚ ¾ÈÀü Çâ»ó, ½ÃÀå Á¢±Ù¼º È®´ë¿¡ ÀÖÀ¸¸ç, ¾÷°è ÆÄÆ®³Ê½ÊÀÇ Á߿伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
The global infection control market size reached USD 28.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 49.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.22% during 2025-2033. North America dominates the market because of robust healthcare infrastructure and widespread adoption of sterilization and disinfection technologies. Moreover, the rapid technological advancements in diagnostic and infection control equipment, the increasing demand in veterinary and animal care settings, rising R&D in infectious disease prevention, and the growing focus on preventing healthcare-associated infections (HAIs) are some of the factors propelling the market growth.
Awareness about hygiene and safety among the public and institutions is rising considerably. Healthcare providers emphasize sterilization and hygiene to avoid cross-contamination. This consciousness spreads to patients, motivating institutions to allocate more resources to infection control. The drive for safer surroundings is consistently driving the need for enhanced products and protocols in the industry. Furthermore, ongoing advancements in disinfection tools and supplies are enhancing both their efficacy and user-friendliness. Automated sterilization systems, enhanced chemical formulations, and real-time monitoring tools are now easily available. These innovations improve results while lowering labor and long-term expenses, making them appealing investments for contemporary healthcare operations. Besides this, the increase in elective and emergency surgeries results in a greater need for sterile environments. Surgical suites necessitate rigorous infection control measures, involving a wide array of supplies and instruments. With the rise in surgical volumes, the necessity for uniform infection control grows, making it a key area of focus for healthcare institutions.
Increasing Geriatric Population
There has been a notable rise in the global geriatric population, which plays a crucial role in shaping the infection control market. As projected by the World Health Organization (WHO), by the year 2030, one in six people globally will be aged 60 and above, with the worldwide senior population anticipated to rise from 1 billion in 2020 to approximately 1.4 billion by 2030. By the year 2050, this figure is expected to be around 2.1 billion. This change in demographics directly affects healthcare systems, as older individuals commonly exhibit weaker immune responses and increased vulnerability to infections. As a result, the need for strict infection control measures in hospitals, nursing homes, and long-term care facilities is growing consistently. Upholding rigorous hygiene standards and implementing cutting-edge sterilization methods are crucial in managing this age demographic. These factors further positively influence the infection control market forecast.
Rising Prevalence of Healthcare-Associated Infections (HAI)
The growing frequency of healthcare-associated infections (HAIs) in hospitals and clinical environments in different areas is emerging as a significant issue, considerably driving the need for efficient infection control strategies. Frequent forms of HAIs, including surgical site infections, catheter-related infections, and ventilator-related pneumonia, represent significant health dangers to patients and lead to prolonged hospitalizations, rising healthcare costs, and elevated morbidity rates. A publication from the European Centre for Disease Prevention and Control indicates that nearly 4.3 million hospital patients in the EU/EEA acquire at least one HAI each year. This concerning statistic highlights the critical necessity for improved infection prevention measures and the implementation of cutting-edge disinfection and sterilization technologies. Healthcare providers are progressively allocating resources to infection control products to guarantee patient safety and adhere to rigorous regulatory requirements. The increasing focus on lowering infection rates is strengthening the growth of the infection control industry.
Expanding Ambulatory Services Industry
The increasing transition towards outpatient services is becoming a major factor in driving the demand for infection control products and technologies. These outpatient care centers, providing medical services without the need for overnight hospital admissions, are becoming more popular because of their convenience, affordability, and accessibility. As reported by IMARC Group, the worldwide ambulatory services market attained a valuation of US$ 3.8 Trillion in 2023 and is expected to expand to US$ 6.3 Trillion by 2032, with a compound annual growth rate (CAGR) of 5.7% from 2024 to 2032. As a result of this expansion, the number of patients receiving care in outpatient settings is increasing, which heightens the need for strict infection control measures. Due to high patient turnover, swift treatment cycles, and the necessity to avert cross-contamination, these facilities demand dependable sterilization, surface disinfection, and personal protective measures. The rising emphasis on safety and regulatory adherence in outpatient settings is anticipated to boost the infection control market revenue.
Technological Advancement and Product Innovation
Advancements in technology for disinfection and sterilization are transformed the infection control market, enhancing its precision, efficiency, and compatibility with changing clinical needs. Advancements in materials, automated systems, chemical substances, and monitoring platforms are enhancing reliability and safety in infection control. A prominent instance is the 2024 introduction of Getinge's Poladus 150, a low-temperature VH2O2 sterilizer designed specifically for heat-sensitive surgical tools. It featured cutting-edge cross-contamination prevention technology designed to minimize healthcare-related infections while optimizing processes in sterile supply units. The system also connected with digital platforms, providing improved traceability and operational effectiveness during hospital reprocessing. Such innovations enable healthcare personnel to execute sterilization procedures with improved uniformity and reduced mistakes. The focus on automation, traceable systems, and intuitive interfaces is minimizing labor-heavy tasks and enhanced adherence to regulations. With increasing awareness among healthcare providers regarding the cost and safety advantages of these technologies, their adoption is accelerating.
Public Health Campaigns and Government Initiatives
Public health campaigns and policy initiatives led by the government are vital in enhancing infection control measures. These initiatives enhance awareness about hygiene, encourage responsible use of antimicrobials, and advocate for best practices in clinical and community environments. Governing bodies frequently assign resources to enhance infection control systems in public hospitals, provide incentives for adherence, and back surveillance initiatives that track infection patterns. National healthcare strategies are progressively prioritizing infection prevention as a key goal, making sure that institutions align with wider health objectives. Educational outreach aimed at both healthcare professionals and the general public reinforces behavior modifications that help lower transmission risks. These campaigns also increase the demand for standardized items, such as disinfectants, sterilization devices, and protective gear. These initiatives enhance public safety while generating ongoing demand, especially in developing areas where awareness and infrastructure are still growing.
Industry Collaboration
Collaborative efforts between manufacturers of medical devices and healthcare stakeholders are essential in promoting the expansion of the infection control market. These collaborations promote awareness, education, and availability of cutting-edge technologies that tackle critical healthcare issues, especially in preventing infections. A recent instance is the collaborative effort by Bactiguard and BD at CRITICARE 2025 in India, where both organizations highlighted the significance of addressing healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), especially in intensive care settings. Throughout the event, clinical sessions emphasized the advantages of Bactiguard-coated catheters in decreasing catheter-associated urinary tract infections (CAUTI) and promoting responsible antibiotic usage. BD has also revealed the imminent release of these cutting-edge devices in the Indian market. These initiatives not only introduce advanced technologies to areas with significant needs but also strengthen the importance of industry partnerships in promoting worldwide infection control objectives, improving patient safety, and broadening market access.
Consumables dominate the market
According to the infection control market outlook, the consumables segment, including disinfectants, sterilization consumables, personal protective equipment (PPE), and other related products, is the largest market segment in the industry. These consumables play a critical role in preventing and controlling the spread of infections across various sectors, such as healthcare, food processing, and public spaces. Disinfectants are vital in healthcare facilities, laboratories, and public spaces to eliminate harmful pathogens on surfaces and minimize the risk of infections. Sterilization consumables, like autoclave bags and indicator tapes, are indispensable in maintaining sterile medical instruments and equipment conditions.
Hospitals and clinics dominate the market
According to the infection control market overview, the hospitals and clinics segment emerged as the largest market share holder in the industry, reflecting the critical role of infection prevention measures in healthcare settings. Hospitals and clinics are high-risk environments where vulnerable patients, healthcare professionals, and visitors come into close contact, making them susceptible to infectious diseases. Infection control is of utmost importance in these settings to curb the spread of healthcare-associated infections (HAIs) and safeguard patient safety. Strict protocols, including hand hygiene, sterilization of medical equipment, and the use of personal protective equipment (PPE), are integral to maintaining a safe and sterile environment. Besides this, with a growing focus on patient care, hospital accreditation, and regulatory compliance, the demand for these solutions in hospitals and clinics remains robust. As healthcare facilities strive to enhance infection prevention measures and reduce the burden of HAIs, the hospitals and clinics segment is expected to continue leading the market.
North America exhibits a clear dominance, accounting for the largest infection control market share
The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Russia, and Others); Europe (Germany, France, the United Kingdom, Italy, Spain, and Others); Latin America (Brazil, Mexico, and Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
According to the infection control market statistics, North America, comprising the United States and Canada, dominate the market, which can be attributed to several key factors driving its growth. The region's significant aging population contributes to the rising demand for infection control measures. For instance, according to an article published by the Population Reference Bureau, the number of people in the United States aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050 (a 47% increase), with the 65-and-over age group accounting for 17% to 23% of the overall population. Moreover, the region's technologically advanced healthcare infrastructure fosters the adoption of innovative infection control solutions, including advanced disinfectants, sterilization technologies, and smart medical devices.
Top companies catalyze the market by introducing innovative solutions and technologies to combat infectious diseases. These companies invest heavily in research and development, creating cutting-edge disinfection and sterilization products that effectively prevent the spread of infections. Their commitment to maintaining stringent quality standards and adherence to regulatory guidelines instills trust among healthcare providers, bolstering their market presence. Moreover, these companies actively engage in educational programs and awareness campaigns, emphasizing the importance of infection prevention and control measures. Continued efforts to expand their global footprint through strategic collaborations and acquisitions further fuel market growth. They address environmental concerns and attract environmentally-conscious consumers by prioritizing sustainability and eco-friendly practices.
The infection control market research report has provided a comprehensive analysis of the competitive landscape in the infection control market. Detailed profiles of all major companies have also been provided.